Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia
Haematologica, 2010 As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (
Asim F. Belgaumi +6 more
doaj +1 more source
Imatinib mesylate resistance and mutations: An Indian experience
Indian Journal of Medical and Paediatric Oncology, 2013 AbstractThe treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory
Sarjana Dutt, Shweta Srivastava
openaire +3 more sources
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
Acta Medica, 2003 The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj +1 more source
Indian Journal of Medical and Paediatric Oncology, 2013 Post Graduate Institute (PGI) Chandigarh is a premier institute of North India. There are approximately 70,000 admissions per year. The adult clinical hematology department sees more than 2000 new patients per year.
Pankaj Malhotra +2 more
doaj +1 more source
Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate. [PDF]
Gels, 2023 Jitrangsri K +4 more
europepmc +1 more source
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]
, 2002 George D. Demetri +20 more
openalex +1 more source
Imatinib Mesylate in Cutaneous Melanoma [PDF]
Journal of Investigative Dermatology, 2004 Enrique J. Andreu +3 more
openaire +3 more sources
Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta [PDF]
, 2002 Jane F. Apperley +18 more
openalex +1 more source
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. [PDF]
Int J Mol Sci, 2023 Bochicchio MT +15 more
europepmc +1 more source
International Journal of Nanomedicine, 2015 Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Marslin G +6 more
doaj